These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 18808311)

  • 1. EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
    Loeffler-Ragg J; Schwentner I; Sprinzl GM; Zwierzina H
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1517-31. PubMed ID: 18808311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.
    Reuter CW; Morgan MA; Eckardt A
    Br J Cancer; 2007 Feb; 96(3):408-16. PubMed ID: 17224925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
    Sharafinski ME; Ferris RL; Ferrone S; Grandis JR
    Head Neck; 2010 Oct; 32(10):1412-21. PubMed ID: 20848399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Brockstein B; Lacouture M; Agulnik M
    J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising newer molecular-targeted therapies in head and neck cancer.
    Wang LX; Agulnik M
    Drugs; 2008; 68(12):1609-19. PubMed ID: 18681486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
    Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
    Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is EGFR really a therapeutic target in head and neck cancers?
    Agarwal V; Subash A; Nayar RC; Rao V
    J Surg Oncol; 2019 May; 119(6):685-686. PubMed ID: 30701564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
    Caponigro F
    Anticancer Drugs; 2004 Apr; 15(4):311-20. PubMed ID: 15057134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
    Fletcher EV; Love-Homan L; Sobhakumari A; Feddersen CR; Koch AT; Goel A; Simons AL
    Mol Cancer Res; 2013 Dec; 11(12):1574-84. PubMed ID: 24048704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-targeting monoclonal antibodies in head and neck cancer.
    Astsaturov I; Cohen RB; Harari PM
    Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.